TIDMERGO

RNS Number : 8274P

Ergomed plc

13 February 2019

PRESS RELEASE

FOR IMMEDIATE RELEASE

Proposed Board and Management Changes

Guildford, UK - 13 February 2019: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that Stuart Jackson, Chief Financial Officer and Board Director has indicated that he will leave the Company in the Summer of 2019 to take up a position as Chief Financial Officer of a listed entity, returning to the energy sector.

Stuart will continue as a Board Director and Chief Financial Officer of Ergomed PLC until a replacement has been secured in order to ensure a smooth transition process. A search for his replacement is underway and the Company will provide an update on his successor in due course.

Dr Miroslav Reljanovic, Executive Chairman of Ergomed, said: "I would like to thank Stuart for his support and contribution to Ergomed. In the time he has been with us, he has made a positive impact on the business and has strengthened our finance and reporting capabilities. I look forward to continuing to work closely with him over the coming months whilst we select his successor. We wish Stuart every success in his new role."

- Ends -

Enquiries:

 
 Ergomed plc                                              Tel: +44 (0) 1483 402 
                                                                            975 
 Miroslav Reljanovic (Executive Chairman) 
 Stuart Jackson (Chief Financial Officer) 
 
 Numis Securities Limited                             Tel: +44 (0) 20 7260 1000 
 Michael Meade / Freddie Barnfield (Nominated 
  Adviser) 
 James Black (Joint Broker) 
 
 
 Consilium Strategic Communications - for             Tel: +44 (0) 20 3709 5700 
  UK enquiries 
 Chris Gardner / Mary-Jane Elliott                  ergomed@consilium-comms.com 
 Matthew Neal / Olivia Manser 
 
 MC Services - for Continental European enquiries        Tel: +49 211 5292 5222 
 Anne Hennecke

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOAGGUAWPUPBPGP

(END) Dow Jones Newswires

February 13, 2019 02:00 ET (07:00 GMT)

Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Ergomed Charts.
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Ergomed Charts.